secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K12B
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001104659-24-076282
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.01, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa completes redomiciliation from Bermuda to UK, shares trade on Nasdaq under same symbol KNSA
--------------------------------------------------------------------------------

- Effective June 27, 2024, Kiniksa redomiciled to UK via Bermuda court-approved scheme of arrangement.
- Shareholders received one-for-one exchange of shares; ~40.4M Class A, 1.8M B, 12.8M A1, 16.1M B1 ordinary shares issued.
- Class A Ordinary Shares continue trading on Nasdaq under symbol KNSA as of June 28, 2024.
- Same executive officers and directors continue; indemnification agreements and equity plans assumed.
- Depositary receipts issued for shares not directly eligible for DTC transfer to avoid UK stamp duty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/0001104659-24-076282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_8k12b.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-076282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer